Yu. V. Vakhabova

Yu. V. Vakhabova

Auto-generated profile, based on publicly available information

Yu. V. Vakhabova

European Medical Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2020 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
EIE. O. Ignatova
E. O. Ignatova
DSD. A. Seryak
D. A. Seryak
MFMikhail Fedyanin
Mikhail Fedyanin
ATAlexey Tryakin
Alexey Tryakin
IPIlya A. Pokataev
Ilya A. Pokataev
МФМ. Ю. Федянин
М. Ю. Федянин
Epstein–Barr virus (EBV) associated gastric carcinoma is a special form of gastric adenocarcinoma that arises against the background of clonal growth of EBV-infected epithelial cells of the gastric mucosa. This subtype of tumors has unique genetic and epigenetic features that determine its characteristic phenotype. Determination of the molecular features of EBV-associated gastric cancer made it possible to identify potential targets for drug therapy of this subtype of tumors. The review presents modern data on the epidemiology and pathogenesis of EBVassociated gastric cancer, describes its unique pathomorphological and molecular features. Particular attention is paid to the prognostic role of EBV infection and drug therapy potentially applicable to the treatment of EBV-positive gastric cancer.

1 January 2026 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ISIgor Samoylenko
Igor Samoylenko
YKYu. M. Kolontareva
Yu. M. Kolontareva
EKE. V. Kogay
E. V. Kogay
NZNatalia Zhukova
Natalia Zhukova
IUI. A. Utyashev
I. A. Utyashev
LDL. V. Demidov
L. V. Demidov
Introduction . Combined immune-targeted therapy is a new registered approach for treating metastatic melanoma. Identifying subgroups of patients who may benefit more from simultaneous rather than sequential administration of triple combination drugs is of current scientific interest to the medical community. Aim . To present a 4-year updated analysis of the efficacy and safety of triple therapy with atezolizumab + vemurafenib + cobimetinib (AVC) in patients with BRAF-mutated advanced melanoma in real-world clinical practice in Russia. Materials and methods . A prospective non-interventional study included 59 patients with metastatic BRAF+ melanoma receiving the triple combination of vemurafenib, cobimetinib, atezolizumab. The primary endpoint was 24-month OS. Additionally, PFS, ORR, and risk factors influencing OS were evaluated. This paper is a 4-year update of a previously published analysis. Results . The median OS in the entire population was 23.67 months (95% CI 13.19–NR), and the median PFS in the entire population was 14.97 months (95% CI 8.00–24.39). An objective response was recorded in 57.6% of patients. Cox multivariate analysis revealed a significant impact of age, presence of lung metastases, and large tumor mass (10–15 cm vs ≤6 cm) on OS. The presence of liver metastases reduced median survival by more than 2.5 times, but no significant effect was proven. BMI, ECOG ≥ 2, CNS metastases, line of therapy, and PD-L1 did not have a statistically significant effect. Conclusion . Triple therapy demonstrates high clinical efficacy in patients with metastatic BRAF+ melanoma in real-world clinical practice in the analyzed population of patients with an unfavorable prognosis – CNS involvement, liver involvement, and second-line and subsequent therapy. Age, the presence of lung metastases, and tumor size were found to be prognostic factors affecting survival.

9 June 2026 in Head and Neck Tumors (HNT)
Verified
Journal Article
Open access
PDF file
YVY. V. Vakhabova
Y. V. Vakhabova
ВВВахабова Ю. В.
Вахабова Ю. В.
SNS. Nidal
S. Nidal
НCНидаль C.
Нидаль C.
PKP. V. Koposov
P. V. Koposov
ЛЕЛойко И. Е.
Лойко И. Е.
Camrelizumab is a monoclonal antibody against programmed cell death protein 1 (PD-1) which demonstrated clinical efficacy in esophageal squamous cell carcinoma including in combination with 1st line chemotherapy cases of advanced disease. The article describes a clinical case of administration of camrelizumab + capecitabin in combination with local ablative intervention in the form of stereotactic radiation therapy for treatment of oligoprogressing esophageal squamous cell carcinoma. This observation shows clinical advisability of continuing immunomodulating therapy in cases of limited tumor progression with simultaneous local control of the lesions with the highest biological activity.